CoCo Therapeutics
From Wikipedia, the free encyclopedia
IndustryPharmaceutical industry
FoundedUnited Kingdom (2013)
Headquarters
United Kingdom
Websitecocotherapeutics.com [dead link]
| Industry | Pharmaceutical industry |
|---|---|
| Founded | United Kingdom (2013) |
| Headquarters | United Kingdom |
| Website | cocotherapeutics |
CoCo Therapeutics is a United Kingdom-based biotechnology company formed in 2013 jointly by King's College London, the Wellcome Trust and Advent Venture Partners.[1] The company will focus on development of therapeutics for Alzheimer's disease which target retinoic acid receptor alpha,[1] specifically building on work originating in the Neuroscience Drug Discovery Unit of King's College, led by Jonathan Corcoran.[2] This work was funded through the Wellcome Trust's Seeding Drug Discovery Initiative.[3]
